The circulation of medicines requires sources to be traceable

Recently, the State Drug Administration issued "on the drug information traceability system construction guidance (draft for comments)" pointed out that in order to achieve "one thing, one yard, the same code chasing" as the direction, the construction of a full variety, the whole process of drug information traceability system. Priority should be given to products of general concern to consumers, such as essential drugs and medical insurance reimbursement drugs. By the end of 2022, the drug information traceability system will be basically completed.
The Draft for Comments points out that drug market license holders (including pharmaceutical production enterprises holding drug approval numbers) and operating and using units shall establish drug traceability systems through information-based means, form an interconnected drug traceability information data chain, and realize that the whole process of drug circulation can be traced and traceable;
"Draft for Comments" requires that the holder should fulfill the responsibility of drug information tracing management, the product at all levels of sales and packaging units assigned a unique traceability logo.
the Draft for Comments, the State Drug Administration should establish a national drug traceability collaborative service platform to encourage enterprises to innovate the way of inquiry. Drug traceability data is owned by "who produces and who owns" and operators may not disclose information to third parties without the authorization of all parties. The period of preservation of drug traceability information records and vouchers shall not be less than 5 years after the expiration of the drug. (Health News)